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Abstract
The kinase Akt plays a central role as a regulator of multiple growth factor input signals, making it 
an attractive anti-cancer drug target. A-443654 is an ATP-competitive Akt inhibitor. 
Unexpectedly, treatment of cells with A-443654 causes paradoxical hyperphosphorylation of Akt 
at its two regulatory sites (Thr308 and Ser473). We explore whether inhibitor-induced 
hyperphosphorylation of Akt by A-443654 is a consequence of disrupted feedback regulation at a 
pathway level or whether it is a direct consequence of inhibitor binding to the ATP binding site of 
Akt. Catalytically inactive mutants of Akt reveal that binding of an inhibitor to the ATP site of 
Akt is sufficient to directly cause hyperphosphorylation of the kinase in the absence of any 
pathway feedback effects. We conclude that ATP-competitive Akt inhibitors impart regulatory 
phosphorylation of their target kinase Akt providing new insights into both natural regulation of 
Akt activation and Akt inhibitors entering the clinic.
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Introduction
Akt (also called protein kinase B or PKB) is a member of the serine/threonine protein kinase 
AGC family and has three isoforms (Akt1, 2 and 3). Akt is a positive regulator of growth 
factor signaling processes including proliferation and survival1–3. As a central node in 
growth factor signaling Akt activity is subject to multiple regulatory inputs1–3. In the 
absence of growth factors, Akt is cytoplasmic and inactive. Upon growth factor stimulation 
of PI3K activity, Akt is recruited to the plasma membrane through binding of its plekstrin 
homology (PH) domain to PIP3 which is produced by PI3K. Translocation of Akt enables 
phosphorylation of residue Thr308 on its activation loop by membrane localized 
phosphoinositide-dependent kinase 1 (PDK1) (see Fig. 1a)4,5. Further activation of Akt 
requires phosphorylation on Ser473 which lies in a C-terminal hydrophobic motif (HM) of 
Akt by the rapamycin insensitive mTORC2 complex6–8. Aberrant activation of Akt has 
been observed in a variety of human cancers through multiple mutations including PI3K 
activating mutations, PTEN phosphatase inactivation, Akt overexpression, Akt point 
mutations in the PH domain which lead to constitutive membrane localization, and 
others1,3,9. The frequent mutational activation of the PI3K/Akt/mTORC1 pathway in 
cancer has led to the development of numerous inhibitors of kinases in the pathway 
including growth factor tyrosine kinase10,11, PI3K3,11–13, PDK13,11,12, Akt3,12, and 
mTORC1 inhibitors3,11,14.
Not all of the inhibitors of the PI3K/Akt/mTORC1 pathway antagonize the pathway. 
Surprisingly, in some patients, the mTORC1 inhibitor rapamycin caused completely 
unanticipated upstream activation, leading to increased Akt activity in tumor tissues15. 
Several groups have shown that rapamycin induced feedback activation of Akt is a result 
from the loss of S6K (p70S6K) destabilization of the scaffolding protein insulin receptor 
substrate-1 (IRS-1)16–19. To develop the most effective PI3K/Akt/mTORC1 pathway 
antagonists, it is important to understand the architecture of negative feedback loops in this 
pathway.
Like rapamycin, another PI3K/Akt/mTORC1 pathway inhibitor, the ATP-competitive 
inhibitor A-443654 (1), has been reported to cause aberrant Akt phosphorylation. A-443654 
was discovered at Abbott laboratories and shown to inhibit the growth of PC-3, MiaPaCa-2, 
and 3T3-Akt1 tumor growth in xenograft animal models20. At the doses required to inhibit 
tumor growth, potent inhibition of downstream Akt signaling was observed. Paradoxically 
however, Akt hyperphosphorylation at Thr308 and Ser473 was induced. The induction of 
Akt hyperphosphorylation by A-443654 was observed in multiple cancer cell lines, and thus 
appears to be a general phenomenon regardless of cell type21. Although 
hyperphosphorylation was initially thought to be caused through Akt/mTORC1/S6K 
negative feedback similar to that described previously for rapamycin, a subsequent study 
indicated that the hyperphosphorylation by A-443654 was observed even in TSC2−/− MEF 
cells21. Since TSC2 is a direct downstream target of Akt and is an inhibitor of mTORC1 
activation, the result suggested that hyperphosphorylation is independent of Akt/
mTORC1/S6K pathway inhibition. However, it is unclear whether Akt controls mTORC1 
activation solely by phosphorylating TSC222,23 and whether TSC2−/− MEF cells possess a 
canonical PI3K/Akt/mTORC1 pathway.
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Since the PI3K/Akt/mTORC1 pathway is central to cancer cell survival and because several 
inhibitors of the pathway have been shown to trigger Akt phosphorylation, we focused on 
understanding the mechanism of Akt hyperphosphorylation by the Akt inhibitor A-443654. 
Using chemical genetics we explore two distinct mechanistic possibilities for how A-443654 
causes Akt hyperphosphorylation. In the first mechanism, A-443654 inhibits a kinase which 
reduces feedback inhibition of Akt phosphorylation. This mechanism is conceptually similar 
to the feedback induced by rapamycin inhibition of mTORC1, which we term extrinsic 
feedback since it involves a signaling cascade. The second possible mechanism of 
hyperphosphorylation we consider is intrinsic to the kinase and relies solely on drug binding 
to Akt. Importantly, the intrinsic model does not involve a pathway mediated feedback 
control mechanism. To distinguish between these potential mechanisms we use a 
combination of Akt chemical genetics, Akt mutations, synthesis of A-443654 analogs, 
fluorescence microscopy and pathway analysis with phosphospecific antibodies.
Results
A-443654 profiling reveals a spectrum of kinase targets
Abbott laboratories reported the ATP-competitive Akt inhibitor A-443654 (in vitro Akt1 Ki 
= 160 pM)20. A-443654 inhibits all three Akt isoforms in FL5.12 cells stably transfected 
with constitutively active myristoylated Akt1/2/3, and showed moderate selectivity when 
screened against related kinases in the AGC family, such as PKA and PKC20. To obtain a 
more complete view of A-443654’s cellular targets we tested it against a larger panel of 
kinases. Of the 220 purified kinases tested, A-443654 inhibited 47 kinases (>90% inhibition 
at 1 µM), including kinases that potentially impinge on the PI3K/Akt pathway such as 
PDK1, S6K, PKA, PKC and GSK3β (Supplementary Table 1 online). The spectrum of 
kinases inhibited by A-443654, especially the targeting of multiple members of the 
PI3K/Akt pathway make deciphering the cellular response to this compound extremely 
challenging.
Design of analog sensitive alleles of Akt isoforms
ATP-competitive kinase inhibitors such as A-443654 often inhibit related protein kinases 
owing to the conserved nature of ATP binding sites across the kinome. To circumvent the 
natural degeneracy in the kinase family we employed a chemical genetic approach to create 
a selective Akt inhibitor. This technique employs the combination of an analogue sensitive 
(as) kinase allele with an as allele specific inhibitor to achieve selective inhibition of Akt as 
shown in Fig. 1a24. The approach exploits a conserved, large hydrophobic residue in the 
kinase active site (termed the gatekeeper), which is in direct contact with the N6 amino 
group of ATP.
To establish this system for all Akt isoforms, mutations enlarging the size of the ATP-
binding pocket were introduced by substituting the gatekeeper methionine with glycine (i.e. 
M227G/M225G/M229G, respectively for asAkt1/2/3). The mutants were expressed in a 
myristoylated form to provide constitutive kinase activation when expressed in HEK293T 
cells. In vitro immunoprecipitation kinase assays revealed that all three isoforms of asAkt 
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retained approximately 30% of the activity of the corresponding wtAkt isoforms 
(Supplementary Fig. 1 online).
Design and synthesis of asAkt specific inhibitors
We next screened inhibitor analogs for potent and selective inhibition of asAkt isoforms. 
The pyrazolopyrimidine1 (PP1) scaffold has proven to be a versatile starting point for 
development of many analog sensitive kinase inhibitors24,25. A structurally diverse series 
of PP1 analogues were screened against asAkt1/2/3 leading to the identification of the 3-
iodobenzyl analogue, 3-IB-PP1 (2)26, inhibiting asAkt1/2/3 with good potency, and without 
inhibition of wtAkt1/2/3 (Fig. 1b). The in vitro potency and selectivity of 3-IB-PP1 for 
asAkt1 (IC50 = 28 nM) vs. wtAkt1 (IC50 >10,000 nM) provides a valuable tool for cellular 
studies of asAkt1 specific functions. In contrast, the potency of 3-IB-PP1 for asAkt2 (IC50 = 
240 nM) and asAkt3 (IC50 = 120 nM) is low for an ATP-competitive kinase inhibitor27. 
Thus, although the availability of a structurally distinct chemical series of selective Akt 
inhibitors afforded by 3-IB-PP1 provides a critical tool for assessing the effects of asAkt1 
inhibition we were concerned about the weak affinity for the asAkt2 and asAkt3 targets.
We therefore sought to design an analog of A-443654 which targets asAkt isoforms but does 
not bind to wtAkt isoforms. Evaluation of the co-crystal structure28 of Akt2 with A-443654 
suggested the C7 position on the indazole ring of A-443654 to be a promising position for 
introducing large substituents which would clash with the gatekeeper methionine of wtAkt 
(Fig. 1c). Extensive SAR studies of various C7-alkyl substituted A-443654 analogues 
revealed the 7-n-propylindazole analogue PrINZ (3) as a potent inhibitor (low nanomolar 
range IC50 values against all asAkt isoforms, see Fig. 1b). As predicted, PrINZ did not 
inhibit wtAkt1/2/3.
Cellular effects of asAkt specific inhibitors
We next proceeded to validate the use of 3-IB-PP1 and PrINZ in cells. To test the 
orthogonality of 3-IB-PP1 and PrINZ, we studied the IGF-1 stimulated activation of Akt in 
non-transfected HEK293 cells. HEK293 cells were treated with A-442654, PrINZ and 3-IB-
PP1, and phosphorylation on Akt and GSK3β, an immediate downstream target of Akt, was 
measured (Fig. 2a). Treatment with A-443654 potently inhibited phosphorylation on GSK3β 
at Ser9 while it induced Akt phosphorylation at Thr308 and Ser473 as reported20. In 
contrast, the phosphorylation level of Ser9 on GSK3β and the two Akt sites was unperturbed 
after treatment with PrINZ and 3-IB-PP1. Collectively, these data suggest that inhibitors 
PrINZ and 3-IB-PP1 are sufficiently selective against wtAkt and potential off-target effects 
of these compounds, if any, do not have observable effects on the upstream and downstream 
signaling of Akt.
We next tested the effect of 3-IB-PP1 and PrINZ on asAkt function in cells to assess 
whether the specific inhibition of Akt downstream signaling and/or specific binding of the 
Akt inhibitors would result in Akt hyperphosphorylation on Thr308 and Ser473. 
Accordingly, the level of asAkt1/2/3 activity in cells was first determined. Akt constructs 
containing a c-Src myristoylation recognition sequence (myr-HA-asAkt) are constituitively 
membrane localized and thus constitutively active without growth factor stimulation29,30. 
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As expected, expression of myr-HA-asAkt1/2/3 and myr-HA-wtAkt1/2/3 in HEK293 cells 
resulted in elevated phosphorylation of GSK3β at Ser9 (Fig. 2b). Elevation of GSK3β 
phosphorylation by myr-HA-asAkt1/2/3 transfection was comparable to that by myr-HA-
wtAkt1/2/3 transfection, confirming the cellular activity of each asAkt isoforms is similar to 
the corresponding activity of wtAkt isoforms.
To determine the effects of the inhibitors in vivo, HEK293 cells were next transfected with 
HA-asAkt1 and treated with serially diluted 3-IB-PP1 or PrINZ (Fig. 2c). HA-asAkt1 
hyperphosphorylation was induced by 3-IB-PP1 and PrINZ in a dose-dependent manner, 
strongly suggesting that induction of phosphorylation results from specific inhibition of Akt 
downstream signaling and/or specific binding of the Akt inhibitors to the kinase and not 
from off-target kinase inhibitory activity as is clearly possible with A-443654. The fact that 
two structurally distinct Akt inhibitors induced Akt hyperphosphorylation indicates that Akt 
hyperphosphorylation is likely a general phenomenon for multiple classes of ATP-
competitive Akt inhibitors.
We then assessed the generality of the phenomenon across the remaining asAkt2 and asAkt3 
isoforms and again observed hyperphosphorylation of these isoforms, demonstrating that 
hyperphosphorylation is consistently induced on all the isoforms of Akt by ATP-competitive 
Akt inhibitors (Fig. 2d).
The downstream consequences of 3-IB-PP1 and PrINZ induced Akt hyperphosphorylation 
were assessed in HEK293 cells transfected with the constituitively activated myr-HA-
asAkt1. Both inhibitors decreased the phosphorylation level of Ser9 on GSK3β in an inverse 
dose-dependent manner to the induction of Akt hyperphosphorylation suggesting that PrINZ 
and 3-IB-PP1 block downstream signaling of Akt while concomitantly inducing Akt 
hyperphosphorylation (Supplementary Fig. 2 online).
Upstream regulators of Akt phosphorylation
Physiological Akt activation is regulated by three upstream kinases1–3: 1) PI3K which 
produces PIP3 for PH domain recruitment of Akt to the membrane; 2) PDK1 
phosphorylation of activation loop Thr308; and 3) mTORC2 phosphorylation of the HM 
Ser473 (Fig. 3a). We asked whether each of these kinase inputs to Akt still regulated 
inhibitor-induced hyperphosphorylation. The role of each upstream kinase was explored 
using both inhibitors of the upstream kinases and mutational analysis of Akt.
Role of membrane localization in hyperphosphorylation
To assess the requirement for Akt membrane translocation in Akt hyperphosphorylation, we 
used the inhibitor PIK90 (4), a selective pan-PI3K inhibitor31. Pre-treatment of HA-
asAkt1/2/3 transfected HEK293 cells with PIK90 significantly attenuated 
hyperphosphorylation of all three asAkt isoforms induced by PrINZ (Fig. 3b). These results 
are consistent with previous studies of the role of PIP3 in both canonical Akt activation1 and 
A-443654 induced Akt hyperphosphorylation21.
The pharmacological blockade of PI3K may influence multiple downstream pathways 
complicating interpretation of the requirement for PI3K activity in inhibitor-induced 
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hyperphosphorylation. As a direct test of the requirement for PIP3 binding by Akt we 
utilized an Akt mutant (R25C), which exhibits significantly decreased affinity for PIP3 (Fig. 
3c)32. Transfection of HA-asAkt1 and HA-asAkt1R25C into HEK293 cells, followed by 
treatment with PrINZ, showed that the R25C mutation greatly reduced the PrINZ induced 
phosphorylation levels on both Thr308 and Ser473 confirming the requirement of Akt 
membrane translocation through Akt binding to PIP3 to achieve hyperphosphorylation.
We next asked if membrane localization was sufficient to cause Akt hyperphosphorylation. 
In cells transfected with constituitively membrane localized myr-HA-asAkt1, treatment with 
PrINZ resulted in hyperphosphorylation of myr-HA-asAkt1 (Fig. 3d). These data suggest 
that membrane localization of Akt is not sufficient to produce hyperphosphorylation of the 
kinase and that Akt localized to the membrane is still subject to drug-induced regulation of 
Thr308 and Ser473 phosphorylation.
We wondered if the constitutively membrane localized construct, myr-HA-asAkt1/2 still 
requires PIP3 binding to be hyperphosphorylated. In other words, Akt hyperphosphorylation 
may require Akt binding to PIP3 but membrane localization itself would not be essential. 
We investigated whether treatment with PIK90 or introduction of the R25C mutation in the 
PH domain affected hyperphosphorylation on myr-HA-asAkt1. Pre-treatment with PIK90 
reduces hyperphosphorylation on HA-asAkt1 induced by PrIDZ (Fig. 3b) while 
hyperphosphorylation on myr-HA-asAkt1 was not inhibited by PIK90 (Supplementary Fig. 
3a online). The constituitively membrane localized myr-HA-asAkt combined with the R25C 
mutation was also studied, with similar results (Supplementary Fig. 3b online). These results 
reveal that hyperphosphorylation of myr-HA-asAkt1 does not require PH domain binding to 
PIP3.
PDK1 and mTORC2 are responsible for phosphorylation
We next explored the mechanistic basis for the regulation by asking whether the upstream 
kinases (PDK1 and mTORC2) are required for drug-induced Akt hyperphosphorylation. The 
phosphorylation of Akt has been the subject of intense study in part because of the fact that 
full activation requires phosphorylation by two kinases on two sites at distant segments of 
the polypeptide. The kinase PDK1 is responsible for phosphorylation at Thr308 during 
normal growth factor stimulation4,5. The kinase responsible for Ser473 phosphorylation has 
been the subject of significant controversy, although it now seems clear that the rapamycin 
insensitive mTOR complex, mTORC2, is the Ser473 kinase7,8. We asked if Akt inhibitor-
induced hyperphosphorylation also relied on these upstream kinases in a cell.
To assess the relevance of PDK1, we used an inhibitor reported by Berlex Biosciences, 
BX-795 (5)33. Screening of BX-795 against a panel of 220 kinases revealed that BX-795 
was selective for only PDK1 within the PI3K-mTORC1 pathway (Supplementary Table 1 
online). HEK293 cells transfected with HA-asAkt1 were pre-treated with BX-795 before 
addition of PrINZ (Fig. 3e). A significant decrease in PrINZ induced Thr308 
phosphorylation was observed, confirming that PDK1 is involved in Akt 
hyperphosphorylation. Interestingly, BX-795 also reduced drug-induced 
hyperphosphorylation at Ser473 as well. Although the mechanistic basis for the BX-795 
effect on Ser473 status is not clear at this point, the same treatment of a non-
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phosphorylatable Thr308 form of Akt, HA-asAktT308A revealed that BX-795 does not affect 
Ser473 phosphorylation status directly (Supplementary Fig. 4 online).
We next investigated the role of mTORC2 using PP242 (6), an ATP-competitive mTOR 
kinase inhibitor, which inhibits both mTORC1 and mTORC2, and does not inhibit any 
PI3Ks or protein kinases in the PI3K-mTORC1 pathway8. When HEK293 cells transfected 
with HA-asAkt1/2/3 were treated with PP242 prior to treatment with PrINZ, 
hyperphosphorylation on Ser473 was completely inhibited (Fig. 3f). The induction of 
phosphorylation at Thr308 was unaffected under these conditions. These results suggest that 
the mTORC2 complex is the kinase responsible for drug-induced Akt hyperphosphorylation 
at Ser473.
Hyperphosphorylation is independent of Akt signaling
Having determined that the same upstream kinases lead to both Akt activation in growth 
factor signaling and inhibitor-induced Akt hyperphosphorylation, we sought to understand 
how Akt inhibitors could lead to its hyperphosphorylation. We consider two broad 
categories of mechanisms—kinase extrinsic and kinase intrinsic. A kinase extrinsic 
mechanism of inhibitor-induced hyperphosphorylation encompasses any form of inhibitor-
induced pathway feedback, which causes the loss of pathway inhibition leading to 
hyperphosphorylation of Akt. A kinase intrinsic mechanism encompasses any drug-induced 
change to the kinase itself which either makes it a better substrate for upstream activators or 
a worse substrate for deactivating phosphatases.
The possibilities for kinase extrinsic forms of inhibitor-induced Akt hyperphosphorylation 
are numerous since so many downstream substrates1–3 are candidates for being in known or 
unknown feedback loops. The most probable extrinsic mechanism for Akt 
hyperphosphorylation is mTORC1/S6K mediated feedback, as has been reported for 
rapamycin15–19. Previous work revealed that hyperphosphorylation by A-443654 occurred 
in TSC2−/− cells, which are defective in activating mTORC1 via Akt and TSC221. 
However, it is possible that mTORC1 activity is controlled by Akt in a TSC2 independent 
fashion. In fact, mTORC1 kinase activity was recently revealed to also be regulated by 
PRAS40 which is a direct target of Akt22,23. In addition, it is unclear whether TSC2−/− 
cells maintain the normal PI3K/Akt/mTORC1 pathway or have compensated in some 
unknown way for the loss of TSC2.
Our studies using DG2 (7), a new selective S6K inhibitor34 however revealed that inhibition 
of S6K does not induce Akt phosphorylation at Thr308 and Ser473 when compared to the 
hyperphosphorylation induced by Akt inhibitors (Supplementary Fig. 5 online). Therefore it 
appears that S6K inhibition is insufficient to cause the large induction of phosphorylation 
seen with direct Akt inhibitors.
Since testing of kinase extrinsic pathways of inhibitor-induced Akt hyperphosphorylation 
requires development of new pharmacological tools for each candidate pathway, we sought 
to rule out the kinase intrinsic model before further investigating the extrinsic model. We 
took advantage of a mutation to Akt which destroys its catalytic activity. Such a mutant is 
incapable of activating any downstream signals via substrate phosphorylation and thus 
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should not induce hyperphosphorylation in the presence or absence of the inhibitor if a block 
of downstream signaling is required to trigger Akt hyperphosphorylation.
Double mutant constructs combining the gatekeeper mutation (e.g. M227G/ M225G for 
asAkt1/2) with mutations that abrogate kinase activity, D292A/D289A for Akt1/2, lacking 
the active-site Asp residue of the DFG motif35 which is required for chelation of 
catalytically essential Mg2+ were prepared and transfected into HEK293 cells. Treatment of 
cells expressing the kinase dead (KD) mutants, myr-HA-asAkt1-KD or myr-HA-asAkt2-KD 
with PrINZ or 3-IB-PP1 induced striking hyperphosphorylation on Thr308 and Ser473. The 
drug-induced hyperphosphorylation on the KD mutants was comparable in magnitude to the 
catalytically active variants, myr-HA-asAkt1 or myr-HA-asAkt2 (Fig. 4a). The non-
myristoyl HA-asAkt1-KD was evaluated as well, with similar results (Fig. 4b). The drug 
induced hyperphosphorylation of the KD variants was further confirmed in multiple cell 
lines (HEK293, MiaPaCa-2, MCF-7 and PC-3), including both transformed and non-
transformed cells (Supplementary Fig. 6 online). These results validate the hypothesis that 
inhibition of Akt signaling is not involved in hyperphosphorylation, and supports the kinase 
intrinsic model in which inhibitor binding to the ATP site triggers hyperphosphorylation.
Drug-induced intrinsic kinase regulatory phosphorylation is unprecedented. Hundreds of 
protein kinase inhibitors have been developed which do not trigger their target kinases to 
become hyperphosphorylated on the activating sites. As a further test of this model and to 
rule out any non-catalytic activity mediated signals from Akt we carried out a double Akt 
transfection experiment. The experiment relies on the co-transfection of HA-asAkt1 and 
flag-wtAkt1 (Fig. 4c). If the occupancy of the ATP site was the only determinant of 
hyperphosphorylation (kinase intrinsic), then only the Akt capable of drug binding (HA-
asAkt1) should be hyperphosphorylated. In cells co-transfected with HA-asAkt1 and flag-
wtAkt1, treatment with PrIDZ revealed Thr308 and Ser473 phosphorylation is induced only 
on HA-asAkt1 and not on drug insensitive flag-wtAkt1 after immunoprecipitation (Fig. 4d). 
The finding demonstrates that feedback mediated by downstream signaling of Akt is not 
involved in hyperphosphorylation of Akt (Fig. 4c). The ability of flag-tagged Akt1 to 
become hyperphosphorylated by Akt inhibitors was confirmed separately (Supplementary 
Fig. 7 online). A second tagged construct of asAkt1 containing mCherry, which exhibits a 
large MW gel shift from endogenous Akt was also studied, with similar results 
(Supplementary Fig. 8 online).
Akt inhibitor induces Akt membrane localization
The finding that drug binding to Akt results in Akt hyperphosphorylation mediated by a 
kinase intrinsic mechanism was particularly surprising in light of our early finding that both 
membrane localization of Akt (Fig. 3b,c and Supplementary Fig. 3 online) and drug binding 
were required for the hyperphosphorylation. One prediction of the kinase intrinsic model of 
inhibitor-induced Akt hyperphosphorylation is that drug binding should cause relocalization 
of Akt from the cytoplasm to the membrane. No known kinase inhibitors that we are aware 
of induce cellular translocation of their target kinase upon binding. To determine whether 
such a drug-induced cellular relocalization was in fact occurring, we carried out 
immunofluorescence studies of Akt. We chose to utilize untransfected HEK293 cells and 
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A-443654, instead of asAkt transfected cells and PrIDZ, to avoid overexpression of the 
kinase. In particular, the untransfected cells maintain the physiological stoichiometry 
between PIP3 and Akt whereas excess asAkt molecules might be mislocalized in asAkt 
overexpressed cells due to insufficient PIP3. After HEK293 cells were treated with 
A-443654, fixed cells were stained with anti-Akt and anti-pThr308 to determine the location 
of Akt and pAkt. In the absence of any growth factor stimulation, treatment with A-443654 
resulted in translocation of Akt to the plasma membrane (Fig. 5). Moreover, the membrane 
localized Akt was phosphorylated at Thr308. In addition, both the translocation and the 
phosphorylation events were inhibited by pre-treatment with PIK90.
Hyperphosphorylation is inhibited by Akti-1,2
Merck has reported an allosteric Akt inhibitor, Akti-1,2 (8), which binds outside of the 
active site and inhibits in vitro kinase activity. Interestingly, in cells Akti-1,2 also inhibits 
growth factor-stimulated activation of Akt by preventing phosphorylation at Thr308 and 
Ser473 in a PH-domain dependent fashion36,37. Although it is still controversial whether 
Akti-1,2 prevents Akt translocation induced by growth factor stimulation36,37, we asked if 
Akti-1,2 inhibits hyperphosphorylation induced by the ATP-competitive inhibitor, PrIDZ. In 
HEK293 cells transfected with HA-asAkt1, treatment with Akti-1,2 prior to induction of 
hyperphosphorylation by PrIDZ resulted in dose-dependent inhibition of 
hyperphosphorylation (Supplementary Fig. 9 online). Akti-1,2 thus inhibits both 
physiological activation of Akt and drug induced Akt hyperphosphorylation. These results 
further support the idea that the upstream regulation of Akt hyperphosphorylation is similar 
for physiological phosphorylation since both exhibit the same pharmacological sensitivity to 
Akti-1,2.
Catalytic activity of hyperphosphorylated Akt
One pharmacologically important question about the drug induced hyperphosphorylation of 
Akt is whether hyperphosphorylated Akt is more catalytically active if the inhibitor were to 
dissociate after Akt is hyperphosphorylated. We measured the in vitro kinase activity of HA-
asAkt1 after inducing hyperphosphorylation by PrIDZ in cells (Fig. 6). HEK293 cells 
transfected with HA-asAkt1 were treated with PrIDZ and hyperphosphorylated HA-asAkt1 
was immunoprecipitated. An in vitro IP kinase assay was carried out after thorough washing 
of the immunoprecipitate to ensure that PrIDZ would dissociate. Hyperphosphorylated 
asAkt1 is revealed to be approximately 10-fold more active than asAkt1 
immunoprecipitated from cells not treated with the active site Akt inhibitor, as anticipated 
based on the phosphorylation status of the two regulatory sites.
Discussion
The widespread involvement of aberrant protein kinase signaling in disease has made the 
development of protein kinase inhibitors a major focus of pharmaceutical research for the 
last ten years. The majority of kinase inhibitors have been shown to inhibit kinase signaling 
pathways through blocking the target kinases’ substrate phosphorylation and subsequent 
downstream pathway components. Paradoxically however, several kinase inhibitors such as 
the mTORC1 inhibitor, rapamycin activate the target pathway due to inhibition of a negative 
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feedback loop16–19. Since the pathways targeted in cancer are growth promoting, it is 
critical to understand which pathways may have active feedback loops and which kinases 
are responsible for their control, in order to avoid inhibitor-induced pathway activation in 
patients15. Other kinase inhibitors including the p38 inhibitor SB20358038, a Raf inhibitor 
ZM33637239, and the Akt inhibitor A-443654 studied here21 induce phosphorylation of 
pathway components. We reasoned that elucidation of the mechanism of inhibitor induced 
phosphorylation of these kinases could influence the development of next generation agents.
Unlike rapamycin, the majority of kinase inhibitors are ATP-competitive making the 
dissection of their effects more difficult because of off-target effects. The first reported Akt 
inhibitor, A-443654 is a case in point. We thus turned to a chemical genetic approach to 
develop highly selective Akt inhibitors. Mutation of the gatekeeper in Akt from methionine 
to glycine enabled selective inhibition by two inhibitors (3-IB-PP1 and PrINZ) which do not 
have effects on kinases which lie upstream or downstream of Akt. All three ATP-
competitive inhibitors induce the same hyperphosphorylation of their target, suggesting that 
A-443654 induced effects will be representative of other Akt inhibitors as well. Indeed, 
Glaxo-Smith Klein discovered another ATP-competitive Akt inhibitor, GSK690693, 
possessing a completely different structure from A-443654, which also induces Akt 
hyperphosphorylation40,41. The chemical genetic inhibitors additionally demonstrated that 
all Akt isoforms (1, 2, and 3) are subject to the same inhibitor-induced 
hyperphosphorylation.
Having conclusive evidence of the class specific nature of Akt hyperphosphorylation 
induced by ATP-competitive inhibitors we turned to dissection of the mechanism. Our 
studies with a new S6K inhibitor revealed that inhibition of S6K, a key mediator of 
rapamycin-driven feedback, is insufficient to cause the large induction of phosphorylation 
seen with direct Akt inhibitors.
The inability to induce Akt hyperphosphorylation through inhibition of downstream 
components of the Akt pathway led us to investigate a non-pathway based mechanism of 
drug-induced Akt hyperphosphorylation. Indeed we observed indistinguishable drug-
induced Akt hyperphosphorylation whether the kinase was active and able to transduce 
signals downstream in the pathway or whether it was inactive.
The central result that the ATP-competitive inhibitor binding is sufficient to induce 
hyperphosphorylation while loss of Akt-downstream signaling inhibition is not, is quite 
surprising. This form of drug-induced kinase regulation is unprecedented to our knowledge. 
We refer to this new form of kinase regulation as “inhibitor hijacking of kinase activation” 
or intrinsic to distinguish it from a loss of negative feedback regulation at a pathway level as 
has been described for rapamycin inhibition of mTORC115–19.
How does drug binding to a kinase induce its hyperphosphorylation in the absence of any 
stimulation of the Akt pathway? Our studies reveal that binding of Akt ligands in the ATP 
pocket template two alterations in the susceptibility of Akt to become phosphorylated. The 
first effect is through drug-induced potentiation of the binding of the Akt PH domain to 
basal levels of PIP3 which promotes membrane location of Akt. If membrane localization is 
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disrupted by pharmacological or genetic means, the drug-induced hyperphosphorylation of 
Akt does not occur. How does drug binding to the catalytic domain of Akt influence PH 
domain binding to PIP3? The results here suggest that the Akt inhibitor sensitizes the PH 
domain to bind basal levels of PIP3 to facilitate membrane location perhaps through a 
conformational change templated by the inhibitor. Recent FRET studies of Akt dynamics 
suggested that the PH domain of Akt is sequestered in the cytoplasm by its interaction with 
Akt kinase domain and is induced to become available to bind PIP337,42.
Our studies with constituitively membrane localized Akt reveal that membrane localization 
alone is not sufficient to induce Akt hyperphosphorylation. Thus, a second drug dependent 
change to Akt in addition to membrane localization is required for hyperphosphorylation to 
occur. This second step involves alteration of the reactivity of the two phosphorylation sites 
(Thr308 and Ser473). The two most easily envisioned mechanisms responsible are either an 
effect on the conformation of Akt to make it more susceptible to kinase phosphorylation or a 
conformational change which makes it less susceptible to phosphatase dephosphorylation. 
Either mechanism alone or a combination of effects could lead to drug-induced Akt 
hyperphosphorylation. However, such regulation is perhaps not surprising given the fact that 
dual phosphorylation of Akt is known to increase its catalytic activity by several orders of 
magnitude, suggesting a means of communication between Thr308-P/Ser-473-P and the 
ATP active site.
Recent FRET studies of Akt suggested that intramolecular interaction between the PH 
domain and kinase domain in the cytoplasm prevents Thr308 phosphorylation by 
PDK137,42. Our results with a constituitively membrane localized Akt construct lacking the 
PH domain, which would be predicted to be constituitively phosphorylated, by analogy to 
the FRET based model, show that hyperphosphorylation was still induced by A-443654 
(Supplementary Fig. 10 online). Thus, it appears that disruption of the PH-kinase domain 
interface is not sufficient alone to induce T308 phosphorylation.
Additional mechanisms for intrinsic activation can be envisioned. Akt associated protein 
partners could be responsible for the drug-induced regulation as seen in some kinases 
regulated by protein-protein association43. Indeed, a number of proteins have been 
suggested to be involved in Akt regulation, including CTMP and Cdc37/HSP9044. A drug-
induced conformational change to Akt which subsequently induces a change in protein-
protein association would be similar to the mechanism observed in regulation of small GTP-
binding protein (small GTPases) such as Ras and Rho45,46. Small GTPases are triggered by 
GTP binding to modulate protein-protein interactions.
In the case of small GTPases, ligand structure (GTP vs. GDP) controls different outputs of 
the protein (GTP-on/GDP-off). Traditionally, kinases have been assumed to use ATP as a 
phosphodonor rather than a regulator of kinase function. Recently however, chemical 
genetic studies of the unfolded protein response regulator, Ire1 have revealed that Ire1 
kinase inhibitors can bypass the need for Ire1 kinase activity to trigger the unfolded protein 
response47,48. Structural studies of the Ire1/kinase inhibitor complex reveal that drug 
binding induces a conformational change in the kinase which triggers oligomerization and 
activation of the RNAse domain of Ire149. This precedent suggests that kinases can be 
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regulated by ligand binding to the ATP binding site in ways independent of the canonical 
ATP dependent phosphotransfer reaction. As more kinases are shown to exhibit catalytic 
activity-independent functions that can be controlled by “inhibitor” binding perhaps it will 
be possible to uncover the function of pseudokinases, the 10% of human kinases which 
naturally lack catalytic activity50.
What do our findings mean for development of kinase inhibitor based therapeutics? Our 
studies revealed that inhibitor induced hyperphosphorylated Akt was extremely active after 
dissociation of ATP-competitive Akt inhibitor. These observations suggest that following in 
vivo treatment with an ATP-competitive Akt inhibitor, if the drug dissociates from Akt, the 
enzyme would be hyper-active and phosphorylate downstream targets, potentially promoting 
oncogenesis. It is important however to realize that our enhanced activity of Akt was only 
observed following isolation of the kinase and that in cells, we never observed increased Akt 
substrate phosphorylation (Fig. 6 and data not shown). Perhaps the phosphatases for T308P 
and S473P are highly active and there is sufficiently rapid dephosphorylation, or our 
washout studies never adequately removed the drug from Akt. Our findings do add to the 
number of studies revealing the importance of various forms of kinase inhibitor induced 
feedback activation observed in cells thus warranting further study of feedback networks, 
both extrinsic (rapamycin-like) and intrinsic (Akt-inhibitor like).
Methods
Chemical synthesis
All compounds except Akti-1/2 were synthesized from commercially available starting 
materials and purified by RP-HPLC. See Supplementary Methods online for complete 
details. Akti-1/2 was purchased from Calbiochem (Akt Inhibitor VIII).
Buffer solutions
Buffer A: 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X, 
2.5 mM Sodium Pyrophosphate, 1 mM β-glycerophosphate, Complete™ Protease Inhibitor 
Cocktail (Roche Applied Science), Phosphatase Inhibitor Cocktail 1 (Sigma-Aldrich), 
Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich) and 20 nM Microcystin LR. Buffer B: 25 
mM Tris (pH 7.5), 10 mM Magnesium Chloride, 5 mM β-glycerophosphate, 0.1 mM 
Sodium Orthovanadate and 2 mM DTT.
Cell-based assay
We used HEK293 cells for cell-based assay in preference to HEK293T line employed for in 
vitro IP kinase assay, because the latter shows constitutive activation of PI3K/Akt signaling, 
as indicated by high level of phosphorylation on Thr308 and Ser473 of Akt, and Ser9 of 
GSK3β (Supplementary Fig. 11 online). In contrast, HEK293 cells show only basal 
PI3K/Akt activity, and are markedly activated by stimulation with IGF-1. Cells were plated 
in six-well dishes and were transfected at 80–90% confluence with a variety of plasmids by 
using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer’s instructions. 
Unless otherwise noted, drug treatments of these Akt-expressing HEK293 cells were carried 
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out in growth factor containing normal media as shown in Cell culture section 
(Supplementary Methods online). In all cases, DMSO inhibitor stocks were used at 1:1000.
Cell lysis
Following drug treatment and/or stimulation, cells were detached with ice cold Ca2+, Mg2+ 
free PBS containing 0.04% EDTA (for HEK293 and HEK293T) or washed with PBS (for 
MCF7, PC-3, MiaPaCa-2 and L6), and then lysed in Buffer A (for HEK293, HEK293T, 
MCF7, PC-3, MiaPaCa-2) or RIPA buffer (L6). Whole-cell lysates were centrifuged (14000 
g at 4°C for 20 min) and then protein amount in supernatants was quantified by using 
Bradford assay (Protein Assay kit, Bio-Rad Laboratories).
Immunoblotting
Cell lysate samples were subjected to SDS/PAGE and proteins were transferred onto 
nitrocellulose membranes (Bio-Rad Laboratories) and blocked with 5% skim milk in 0.1% 
Tween 20/Tris Buffered Saline (TBST). The nitrocellulose membranes were probed with 
various antibodies in 5% BSA/TBST described in the figure legends (all primary antibodies 
from Cell Signaling Technology). Detection of primary antibodies was performed using 
appropriate peroxidase-conjugated IgGs (Pierce Biotechnology or Santa Cruz 
Biotechnology) in 5% BSA/TBST and protein signals were visualized using enhanced 
chemiluminescence (Pierce Biotechnology) by exposure to CL-X Posure™ film (Pierce 
Biotechnology).
Immunoprecipitation
After cell lysis in Buffer A, protein amount of each sample was adjusted to the same. Each 
sample was immunoprecipitated over night at 4°C with either Anti-HA Affinity Matrix 
(Roche Applied Science) or Anti-Flag® M2 Agarose (Sigma-Aldrich) each blocked in 
advance with 1% BSA in PBS for 3 hrs at 4°C. After washing three times with Buffer A, the 
immunoprecipitates were denatured by boiling with loading buffer, and subjected to 
immunoblotting.
Immunofluorescence
HEK293 cells were cultured on cover slips coated with poly-L-lysine (Aldrich). After 
treatment with drugs described in the figure legends, cells were washed once with 
phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde in PBS for 15 min at 
room temperature (rt). After washing three times with PBS, cells were permeabilized with 
0.2% Triton X-100 in PBS for 5 min and then washed three times with PBS. After blocking 
with 5% BSA/PBS for 1 h, cells were incubated over night at 4°C with mouse monoclonal 
anti-Akt antibody and rabbit monoclonal anti-pAkt (p308) antibody (Both from Cell 
Signaling Technology) in 2% BSA/PBS. After washing three times with PBS, cells were 
further incubated for 1 h at rt with Alexa Fluor® 488-conjugated goat anti-rabbit IgG and 
Alexa Fluor® 568-conjugated goat anti-mouse IgG1 (Both from Invitrogen). After washing 
three times with PBS and once with water, cover slips were mounted on cover slides with 
VECTASHIELD® mounting medium (Vector Labs) containing 4',6-diamino-2-
phenylinodole (DAPI). Fluorescent images were obtained with a Zeiss Axiovert 200M 
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florescence microscope equipped with an apotome (which permits optical sectioning of 
cells) using AxioVision Rel. 4.6 software. Images shown in figure were taken with a Zeiss 
Plan-Apochromat 63×/1.4 Oil Dic objective.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chemical genetic strategy for achieving Akt-specific inhibition
(a) Schematic representation of wild type Akt inhibition versus asAkt inhibition. A-443654 
inhibits all three isoforms of endogenous Akt (left), while asAkt specific inhibitors such as 
PrIDZ and 3-IB-PP1 inhibit only the corresponding asAkt isoform, which can be 
overexpressed in a cell (right). (b) Chemical structures and in vitro inhibitory activity of Akt 
inhibitors against all three Akt isoforms. The asAkt inhibitors specifically block asAkt 
activity. IC50 values were determined by an in vitro IP kinase assay for myr-HA-wtAkt1/2/3 
and myr-HA-asAkt1/2/3 expressed in HEK293T cells. (C) Co-crystal structure of Akt2 with 
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A-443654 (PDB: 2JDR)28. The gatekeeper methionine in Akt2 and A-443654 are shown in 
stick representation. Colors are as follows: light blue, carbon; red, oxygen; blue, nitrogen; 
yellow, sulfur.
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Figure 2. Cellular effects of asAkt transfection and asAkt specific inhibitor treatment
(a) HEK293 cells were serum-starved overnight and then treated with PrINZ, A-443654 or 
3-IB-PP1 for 20 min prior to stimulation with 50 ng/ml IGF-1 for an additional 10 min. Cell 
lysates were analyzed for Akt (Thr308, Ser473) and GSK3β (Ser9) phosphorylation by 
immunoblotting. (b) HEK293 cells were transfected with myr-HA-wtAkt1/2/3 or myr-HA-
asAkt1/2/3. Cell lysates were analyzed for Akt (Ser473 and Thr308) and GSK3β (Ser9) 
phosphorylation by immunoblotting. (c) HEK293 cells transfected with HA-asAkt1 were 
treated for 30 min with serially diluted PrINZ or 3-IB-PP1. Cell lysates were analyzed for 
Akt (Thr308, Ser473) phosphorylation by immunoblotting. (d) HEK293 cells transfected 
with HA-asAkt1/2/3 were treated for 30 min with 2.5 µM PrINZ or 10 µM 3-IB-PP1. Cell 
lysates were analyzed for Akt (Thr308, Ser473) phosphorylation by immunoblotting.
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Figure 3. Pharmacological and genetic dissection of upstream regulators of Akt inhibitor-
induced Akt hyperphosphorylation
(a) Analyzed regulators of physiological Akt activation include: 1) PI3K, which produces 
PIP3 for PH domain recruitment of Akt to the membrane; 2) PDK1, which phosphorylates 
Thr308; and 3) mTORC2, which phosphorylates Ser473. PI3K, PDK1 and mTORC2 are 
inhibited: PIK90, BX-795 and PP242, respectively. (b) HEK293 cells transfected with HA-
asAkt1/2/3 were treated with 2.5 µM PIK90 for 10 min prior to the addition of 2.5 µM 
PrINZ for an additional 30 min. Cell lysates were analyzed for Akt (Thr308, Ser473) 
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phosphorylation by immunoblotting. (c) HEK293 cells transfected with either HA-asAkt1 or 
HA-asAkt1R25C were treated with 2.5 µM PrINZ for 30 min. Cell lysates were analyzed for 
Akt (Thr308, Ser473) phosphorylation by immunoblotting. (d) HEK293 cells transfected 
with myr-HA-asAkt1 were treated with 2.5 µM PrINZ for 30 min. Cell lysates were 
analyzed for Akt (Thr308, Ser473) phosphorylation by immunoblotting. (e) HEK293 cells 
transfected with HA-asAkt1/2/3 were treated with 10 µM BX-795 for 10 min prior to the 
addition of 2.5 µM PrINZ for an additional 30 min. Cell lysates were analyzed for Akt 
(Thr308, Ser473) phosphorylation by immunoblotting. (f) HEK293 cells transfected with 
HA-asAkt1/2/3 were treated with 2.5 µM PP242 for 10 min prior to the addition of 2.5 µM 
PrINZ for an additional 30 min. Cell lysates were analyzed for Akt (Thr308, Ser473) 
phosphorylation by immunoblotting.
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Figure 4. Hyperphosphorylation is independent of Akt signaling and results from inhibitor 
binding to Akt
(a) HEK293 cells transfected with either kinase active myr-HA-asAkt1/2 or kinase dead 
(KD) form of myr-HA-asAkt1/2 were treated for 30 min with 2.5 µM PrINZ or 10 µM 3-IB-
PP1. Cell lysates were analyzed for Akt (Thr308, Ser473) and GSK3β (Ser9) 
phosphorylation by immunoblotting. (b) HEK293 cells transfected with either kinase active 
HA-asAkt1 or kinase dead (KD) form of HA-asAkt1 were treated for 30 min with 2.5 µM 
PrINZ or 10 µM 3-IB-PP1. Cell lysates were analyzed for Akt (Thr308, Ser473) and GSK3β 
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(Ser9) phosphorylation by immunoblotting. (c) Schematic representation of the expected 
outcomes due to extrinsic and intrinsic regulation of Akt upon treatment with PrIDZ and co-
transfection of HA-asAkt1 and flag-wtAkt1. If pathway mediated feedback is causing Akt 
hyperphosphorylation (kinase extrinsic) then all Akt molecules in the same cell including 
both HA-asAkt1 and flag-wtAkt1 should be hyperphosphorylated equally. In contrast, if the 
occupancy of the ATP site was the only determinant of hyperphosphorylation (kinase 
intrinsic), then only the Akt capable of drug binding (HA-asAkt1) should be 
hyperphosphorylated. (d) HEK293 cells co-transfected with HA-asAkt1 and flag-wtAkt1 
were treated for 30 min with various concentration of PrINZ. Cell lysates were 
immunoprecipitated by using either anti-HA or anti-flag antibody and then the 
immunoprecipitates were analyzed for Akt (Thr308, Ser473) phosphorylation by 
immunoblotting.
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Figure 5. The Akt inhibitor A-443654 induces Akt membrane localization
After treatment of HEK293 cells with various conditions described below, cells were fixed 
and stained with rabbit anti-Akt or mouse anti-pAkt (p308) followed by Alexa 488-
conjugated goat anti-rabbit and Alexa 568-conjugated goat anti-mouse, and examined by 
fluorescence microscopy. Cells were treated with vehicle (DMSO) for 15min (top panel), 
treated with 2.5 µM A-443654 for 15 min (middle panel), or treated with 2.5 µM PIK90 for 
10 min prior to the addition of 2.5 µM A-443654 for further 15 min (bottom panel). Scale 
bar 10 µm.
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Figure 6. Hyperphosphorylated Akt is hyper-active in vitro after dissociation of Akt inhibitor
HEK293 cells transfected with HA-asAkt1 were cultured either with or without serum 
overnight and then treated with 2.5 µM PrIDZ for 30 min before stimulation with IGF-1 (50 
ng/ml) for 10 min. HA-asAkt1 was immunoprecipitated from cell lysates and assayed for 
Akt activity. Data are represented as mean ± SEM (n=8) and as relative values to IGF-1 
stimulated HA-asAkt1 activity. The immunoprecipitates were analyzed for Akt (Thr308, 
Ser473) phosphorylation by immunoblotting.
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